Schroder Investment Management Group Purchases 260,940 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Schroder Investment Management Group grew its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 87.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 558,798 shares of the biotechnology company's stock after purchasing an additional 260,940 shares during the period. Schroder Investment Management Group owned about 0.20% of Exelixis worth $18,831,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership grew its position in Exelixis by 104.4% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 3,159,395 shares of the biotechnology company's stock worth $105,208,000 after acquiring an additional 1,613,482 shares in the last quarter. denkapparat Operations GmbH acquired a new stake in shares of Exelixis in the fourth quarter valued at about $713,000. New Age Alpha Advisors LLC bought a new position in shares of Exelixis in the fourth quarter worth about $2,103,000. Norges Bank bought a new stake in Exelixis during the 4th quarter valued at approximately $94,867,000. Finally, NEOS Investment Management LLC lifted its holdings in shares of Exelixis by 21.4% during the fourth quarter. NEOS Investment Management LLC now owns 49,256 shares of the biotechnology company's stock worth $1,640,000 after buying an additional 8,674 shares during the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Exelixis

In other Exelixis news, Director Bob Oliver sold 18,647 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $37.25, for a total transaction of $694,600.75. Following the transaction, the director now directly owns 33,514 shares in the company, valued at approximately $1,248,396.50. This represents a 35.75 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Patrick J. Haley sold 52,636 shares of the business's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $36.98, for a total value of $1,946,479.28. Following the completion of the sale, the executive vice president now directly owns 303,310 shares of the company's stock, valued at $11,216,403.80. The trade was a 14.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 140,343 shares of company stock worth $5,177,234 over the last three months. Company insiders own 2.85% of the company's stock.

Remove Ads

Exelixis Stock Up 0.8 %

Shares of NASDAQ EXEL traded up $0.27 during midday trading on Monday, reaching $34.84. 2,918,691 shares of the company were exchanged, compared to its average volume of 2,152,747. Exelixis, Inc. has a one year low of $20.14 and a one year high of $40.02. The stock has a market cap of $9.75 billion, a P/E ratio of 19.68, a PEG ratio of 1.13 and a beta of 0.57. The stock's 50-day moving average price is $35.94 and its 200-day moving average price is $33.70.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, equities research analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on EXEL. Truist Financial upped their price target on Exelixis from $42.00 to $43.00 and gave the company a "buy" rating in a report on Monday, January 27th. Brookline Capital Management began coverage on shares of Exelixis in a research report on Monday, December 23rd. They set a "buy" rating on the stock. StockNews.com raised shares of Exelixis from a "buy" rating to a "strong-buy" rating in a report on Wednesday, February 19th. Stifel Nicolaus increased their target price on Exelixis from $30.00 to $36.00 and gave the stock a "hold" rating in a report on Wednesday, February 12th. Finally, BMO Capital Markets cut shares of Exelixis from an "outperform" rating to a "market perform" rating and raised their price objective for the company from $36.00 to $40.00 in a research report on Friday, December 20th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Exelixis currently has a consensus rating of "Moderate Buy" and a consensus target price of $37.59.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.